Key points from article :
Nuritas, a Dublin-based biotech company, has raised $42 million in Series C funding, led by M&G Investments and McWin Capital Partners, with support from Grosvenor and the European Circular Bioeconomy Fund.
Founded in 2014, Nuritas uses its proprietary AI platform, Magnifier, to discover bioactive peptides from natural sources. These peptides, short chains of amino acids, are clinically validated to support health issues such as muscle repair and skin health. Nuritas’ platform accelerates discovery by up to 50 times compared to traditional methods, with a clinical success rate exceeding 80%. The peptides are integrated into foods, dietary supplements, and cosmetics, addressing health challenges linked to aging and modern lifestyles.
This funding will enable Nuritas to scale its global operations, enhance production capabilities, and strengthen scientific teams. The company also plans to introduce three new peptide products by 2025, building on innovations like PeptiStrong, which aids muscle repair, and PeptiYouth, promoting skin health. Both products have been validated through human clinical trials and are already used in the U.S. and Asian markets.
Nuritas emphasizes sustainability, using plant-based sources and minimizing waste during production, aligning with the growing demand for environmentally responsible health solutions. With partnerships with global leaders like Nestlé, Mars, and Givaudan, Nuritas demonstrates the versatility of its peptides across sectors.
Dr. Nora Khaldi, Founder and CEO, highlighted the mission to create science-backed ingredients that address pressing health challenges, empowering healthier lifestyles worldwide. The investment also brings new expertise to the company’s board, positioning it as a leader in AI-driven ingredient innovation. Published in Longevity.Technology, this milestone underscores Nuritas' role in revolutionizing healthspan solutions and transforming natural compounds into impactful, accessible health products globally.
